Modality
Degrader
MOA
KIF18Ai
Target
FGFR
Pathway
Innate Imm
ALSADPKD
Development Pipeline
Preclinical
~Jan 2022
→ ~Apr 2023
Phase 1
~Jul 2023
→ ~Oct 2024
Phase 2
Jan 2025
→ Jun 2029
Phase 2Current
NCT08249629
1,242 pts·ALS
2025-01→2029-06·Terminated
NCT08079750
1,430 pts·ALS
2025-12→2028-04·Terminated
2,672 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-05-182mo awayEnrollment Complete· ADPKD
2028-04-122.0y awayPh2 Data· ALS
2029-06-213.2y awayPh2 Data· ALS
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Termina…
P2
Termina…
Catalysts
Enrollment Complete
2026-05-18 · 2mo away
ADPKD
Ph2 Data
2028-04-12 · 2.0y away
ALS
Ph2 Data
2029-06-21 · 3.2y away
ALS
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08249629 | Phase 2 | ALS | Terminated | 1242 | EASI-75 |
| NCT08079750 | Phase 2 | ALS | Terminated | 1430 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |